05
Retatrutide, tesamorelin and MOTS-c compared
One synthetic combination, one stimulus to hormone secretion, one peptide the body already makes. I’d begin with those jobs before compiling a list of hoped-for benefits.
What enters the experiment
| Compound | Supplied or measured | Response being investigated |
|---|---|---|
| Tesamorelin | A synthetic GHRH analogue | The pituitary secretes GH; the liver produces IGF-1. |
| Retatrutide | An engineered GIP/GLP-1/glucagon receptor agonist | Direct receptor activity combines appetite, insulin and energy-expenditure effects. |
| MOTS-c | Added peptide in animal experiments; endogenous peptide measured in human studies | Cellular metabolic responses, physical performance in mice, and human biomarker associations. |
The tesamorelin pulsatility study, retatrutide receptor study and MOTS-c biology review make those arrangements concrete. Each begins at a different point in the body’s signaling machinery.
Outcome measures
The retatrutide obesity trial reports body-weight change: -24.2% at 48 weeks in its highest-dose group versus -2.1% for placebo, in a trial of 338 adults. The tesamorelin meta-analysis reports a mean visceral-fat difference of -27.71 cm2 across five randomized trials in HIV-associated lipodystrophy. One number concerns whole-body weight and the other an abdominal-fat area. Their units and populations make a numerical league table misleading.
MOTS-c’s human hemodialysis cohort measured an existing peptide and its association with later events. That study contributes no treatment-effect number to compare with either trial result. I prefer a table with that gap left visible to a score that rewards all three for being interesting.
Liver-fat findings also use particular measures. Retatrutide’s MASLD substudy reports relative liver-fat change, whereas the tesamorelin JAMA trial reports a net hepatic lipid-to-water change in adults with HIV. Similar organ, different comparisons.
Approval status and safety questions
| Compound | Status in the supplied record | Unresolved issue |
|---|---|---|
| Tesamorelin | FDA-approved for excess abdominal fat in adults with HIV-associated lipodystrophy | IGF-1 elevation, glucose effects and safety over longer treatment periods. |
| Retatrutide | Investigational; phase 3 ongoing; no regulatory approval | Gastrointestinal adverse events, pulse changes and longer-term outcomes. |
| MOTS-c | No FDA approval or completed human efficacy trial of the administered peptide | Human exposure, dose-response and adverse effects remain unestablished. |
The tesamorelin monograph describes its narrow indication; the retatrutide review describes the clinical program and cautions; the MOTS-c review maps the largely preclinical biology. Tesamorelin and MOTS-c also carry anti-doping prohibitions.
A laboratory research label supplies no assurance of identity, purity or sterility for human treatment. The FAQ addresses the names and practical queries that tend to obscure these differences. I object to grading these compounds on a common scale when the experiments ask such different questions.